Article

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in Egfr-Mutant Lung Adenocarcinoma

2024-02-12

Abstract excerpt

Mutations in epidermal growth factor receptor (EGFR) occur in about 48% of Asian and 19% of Western patients with lung adenocarcinoma (LUAD), leading to its constitutive activation and subsequent uncontrolled cell proliferation. To counteract this, tyrosine kinase inhibitors (TKIs) have been developed, targeting EGFR activity. However, the emergence of metastases and resistance mutations often undermines the durab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 687fd8ad-c395-51fd-b624-f4eb1871174c
DOI: 10.20944/preprints202402.0640.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in Egfr-Mutant Lung AdenocarcinomaDOI 10.20944/preprints202402.0640.v1Read

Knowledge-based mechanistic modeling accurately predicts disease progression with gefinitib in EGFR-mutant lung adenocarcinomaSemantic proximity Read

A novel artificial lung organoid for simulating a patient derived adenocarcinoma of lung for personalized oncologySemantic proximity Read

Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.Semantic proximity Read

Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.Semantic proximity Read

A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects.Semantic proximity Read

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.Semantic proximity Read

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Semantic proximity Read

Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.Semantic proximity Read

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.Semantic proximity Read

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.Semantic proximity Read

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In VivoSemantic proximity Read

Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models.Semantic proximity Read